Evidence map›Paper›PMID 41188773›Full record

ArticleBMC cancer2025

C1QTNF1-AS1/miR-346 axis suppresses osteosarcoma progression via dual inhibition of LDHA/PDK1-mediated Warburg effect.

Yu Zhang, Jingyi Hou, Kaikai Ding, Bowen Xu, Ning Yang, Yubo Li, Bin Chen, Naiqiang Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yu ZhangGraduate School of Chengde Medical University, Chengde, Hebei, 067000, China.
Jingyi HouGraduate School of Chengde Medical University, Chengde, Hebei, 067000, China.
Kaikai DingGraduate School of Chengde Medical University, Chengde, Hebei, 067000, China.
Bowen XuGraduate School of Chengde Medical University, Chengde, Hebei, 067000, China.
Ning YangHebei Key Laboratory of Panvascular Diseases, Affiliated Hospital of Chengde Medical University, Chengde, Hebei, 067000, China.
Yubo LiDepartment of Minimally Invasive Spine Surgery, Affiliated Hospital of Chengde Medical University, 36 Nanyingzi Street, Chengde, Hebei, 067000, China.
Bin ChenDepartment of Minimally Invasive Spine Surgery, Affiliated Hospital of Chengde Medical University, 36 Nanyingzi Street, Chengde, Hebei, 067000, China.
Naiqiang ZhuDepartment of Minimally Invasive Spine Surgery, Affiliated Hospital of Chengde Medical University, 36 Nanyingzi Street, Chengde, Hebei, 067000, China. zhunq2010@163.com.ORCID http://orcid.org/0000-0002-9540-4408

Funding

Natural Science Foundation of Hebei Province CYFYLL2022091
6 · The paper itself

Abstract

purposeOsteosarcoma (OS) relies on the Warburg effect for aggressive growth and chemotherapy resistance, but strategies to disrupt this metabolic adaptation remain limited. This study aimed to identify novel noncoding RNA regulatory mechanisms governing the Warburg effect in OS and explore potential therapeutic targets. MATERIALS AND

methodsIntegrated bioinformatics analysis (GEO dataset GSE126209) was combined with experimental validation (qPCR, Western blotting, dual-luciferase assays) to characterize interactions between long noncoding RNA (LncRNA) C1QTNF1-AS1, microRNA-346 (miR-346), and key glycolytic enzymes. Functional assays (cell proliferation, migration, invasion and glucose/lactate/ATP measurements) were performed to assess metabolic and oncogenic effects in OS cell lines.

resultsWe identified a previously uncharacterized C1QTNF1-AS1/miR-346/PDK1-LDHA regulatory axis. miR-346 uniquely suppressed both pyruvate dehydrogenase kinase 1 (PDK1) and lactate dehydrogenase A (LDHA)-rate-limiting nodes in lactic acid production-whereas C1QTNF1-AS1 synergistically enhanced their activities. This dual-targeting mechanism induced a co-metabolic crisis in OS cells, reducing lactate output and reversing chemotherapy resistance in vivo.

conclusionThe C1QTNF1-AS1/miR-346 axis reveals a treatable vulnerability in OS metabolism. miR-346 is proposed as a first-class multitarget RNA therapy to weaken the Warburg effect, offering a novel strategy for metabolic intervention in OS.

Indexed as

Bone NeoplasmsL-Lactate DehydrogenaseMicroRNAsOsteosarcomaPyruvate Dehydrogenase Acetyl-Transferring KinaseRNA, Long NoncodingWarburg Effect, OncologicAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansLactate Dehydrogenase 5Lactate Dehydrogenase 5LDHA protein, humanL-Lactate DehydrogenaseMicroRNAsPDK1 protein, humanPyruvate Dehydrogenase Acetyl-Transferring KinaseRNA, Long NoncodingC1QTNF1-AS1LDHAMiR-346PDK1Warburg effect

Identifiers

PMID41188773
PMCPMC12584532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.